Company fine-tuned Human proIslet Peptide structure and used it to decrease glucose levels.

CureDM says it achieved two preclinical drug discovery milestones related to diabetes-related product.

The first milestone was completion of pharmacokinetic studies of the CureDM Human proIslet Peptide (HIP) in serum. These studies defined structural improvements that stabilize the peptide for human therapeutic use.

The second milestone was to show the ability of HIP to reverse diabetes in mice. The well-recognized streptozotocin-induced diabetes model was used to show a significant decrease in glucose levels in the treatment group as compared with the placebo group. In addition, the treatment groups required progressively less insulin over the course of the 28-day study, and one entire group, treated with a CureDM HIP derivative, was actually completely insulin-free by day 21. The blinded, placebo-controlled studies were conducted at Calvert Laboratories in Scranton, PA.

“The ultimate goal is to change diabetes from a chronic, progressive disease to a transient metabolic disorder,” comments Loraine V. Upham, CEO. “Ultimately, we believe that HIP will be shown to be capable of restoring normal glucose metabolism in humans.”

Previous articleDowpharma Enters into Multiproduct License Agreement with Merck
Next articleDanish Court Halts Sale of Ranbaxy’s Generic Lipitor